Home / Europe / Poland / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 life sciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our life sciences and healthcare teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

Our co-operation with the team was delightful.
Chambers, 2016

With over 480 international specialist lawyers across CMS and the support of the Life Sciences & Healthcare Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences and healthcare business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences and healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

In Poland we are one of the largest players in the market. The close cooperation of almost 150 lawyers in our Warsaw and Poznan offices allows the Life Sciences & Healthcare Practice to offer comprehensive industry-focused advice. Our clients trust us with their toughest business challenges, spanning from clinical trials, pricing and reimbursement, IP, to high profile compliance issues and M&A transactions.

Highlights of our experience in Lifesciences in Poland
A leading global medical device and pharmaceutical company on regulatory issues concerning both medical devices and medicinal products, in such areas as compliance, reimbursement, marketing, promotion...
29/11/2021
Global Life Sciences & Healthcare Festival 2021 - Virtual
Join us for this year's Global Life Sciences & Healthcare Festival 2021 - Virtual from 29 November to 2 December.  Day 1: Artificial Intelligence in Life Sciences & Healthcare: New business models in a changing legal en­vir­on­ment­Busi­ness models for AI

Feed

27/03/2024
Cannabis law and legislation in Poland
Medical use Polish legislation does not generally allow the growing of cannabis that contains more than 0.3% THC in flowering or fruiting tops of plants from which the resin has not been removed (Non-Fibrous...
25/03/2024
Patentability of inventions relating to diagnostic methods at the EPO
Under Article 53(c) of the European Patent Convention (EPC), diagnostic methods practised on the human or animal body are excluded from patentability. The purpose behind this exclusion is to avoid patent...
30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
08/01/2024
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...
22/12/2023
CMS advises EBRD and DFC on financing for the development of Ukrainian...
International law firm CMS has advised the international financial institution, European Bank for Reconstruction and Development (EBRD), and the development finance institution, the United States’ International...
18/12/2023
Digital health apps and telemedicine in Poland
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...
08/11/2023
CMS Life Sciences Vital Signs, Winter 2023
2023 has seen some significant legal developments impacting the life sciences industry, and as we look ahead to 2024, there are several important developments which we would like to keep our clients informed...
28/09/2023
EP Case Law in Brief: Erroneous Disclosures
“Mistakes in a document do not in themselves constitute prior art such as to prevent the grant of a patent.”So begins section I.C. 4.9 of the Case Law of the Boards of Appeal. This statement, and...
28/06/2023
UK announces £21m AI roll-out across NHS
IntroductionOn 23 June 2023, the UK government announced a £21 million fund aimed at accelerating the deployment of Artificial Intelligence (“AI”) across the National Health Service (“NHS”)...
12/06/2023
CMS updates Global Expert Guide to Digital health apps and telemedicine
Digitisation is advancing steadily. Its pioneering innovations challenge all parties involved.One of the most important aspects in this area is the huge potential that lies in the digitisation of healthcare.In...
12/05/2023
Poland adopts new regulation regarding advertisement of medical devices
After months of preparation, Poland has approved a new Regulation regarding advertisement of medical devices, which will come into force on 13 May 2023. In addition to the statutory requirements on advertising...